Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. operates as a contract research organization (CRO) in China, primarily focused on the development of chemical and peptide-based pharmaceutical products. Its portfolio includes generic small-molecule chemical drugs and peptide therapies designed to treat a range of conditions such as impetigo, acne, renal anemia, hyperparathyroidism in chronic kidney disease patients on dialysis, and various pain-related ailments. Beyond drug development, the company offers a comprehensive array of research and evaluation services. These encompass testing for packaging material compatibility, detailed impurity profiling, extractables and leachables studies, and thorough safety assessments. Sun-Novo also provides support for consistency evaluations, facilitates clinical research, and delivers expert consulting and agency services for regulatory submissions. Furthermore, it conducts a full spectrum of GLP-compliant bioanalysis and pharmacokinetics-pharmacodynamics (PK/PD) studies, including pharmacokinetic, immunogenic, pharmacodynamic, and biomarker analyses. The company was founded in 2009 and is headquartered in Beijing, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.